Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease
Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease. Read the full a...
12 Heinä 202317min
Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis
Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort ...
7 Kesä 202312min
Adelina Artenie on the incidence of HIV and HCV in people who inject drugs
Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or g...
10 Touko 202317min
Johan Burisch on the costs of inflammatory bowel disease in high-income settings
Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in h...
12 Huhti 202320min
Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease
Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease. Read the f...
8 Helmi 202321min
Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer
Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable panc...
23 Tammi 202320min
Dan Turner on vedolizumab in children with IBD
Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD. Read the full article: Outcomes, dosing, and predic...
6 Tammi 202314min
Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection
Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infect...
9 Marras 202215min
